Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bernd-Rüdiger Balda
Michael Hertl

Showing results (71-80 of 180) with videos related to

Pageof 18
Sort By:
Frontiers in Medicine|October 21, 2022
Therapeutic strategies for oral lichen planus: State of the art and new insightsDario Didona, Raffaele Dante Caposiena Caro, Antonio Manuel Sequeira Santos, et al.
Clinical Immunology (Orlando, Fla.)|November 23, 2006
Detection of low avidity desmoglein 3-reactive T cells in pemphigus vulgaris using HLA-DR beta 1*0402 tetramersChristian Veldman, Rüdiger Eming, Sonja Wolff-Franke, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|April 18, 2009
Results of a survey of German dermatologists on the therapeutic approaches to pemphigus and bullous pemphigoidSilke C Hofmann, Ocko Kautz, Michael Hertl, et al.
European Journal of Dermatology : EJD|October 17, 2018
Adjuvant high-dose intravenous immunoglobulins for recalcitrant erosive oral lichen planus: mixed clinical responsesArmin Bender, Caroline Fix, Verena Eubel, et al.
Journal of Dermatological Science|May 23, 2020
Detection of autoantibodies against alpha-2-macroglobulin-like 1 in paraneoplastic pemphigus sera utilizing novel green fluorescent protein-based immunoassaysCecilia Bazzini, Nadja Begré, Bertand Favre, et al.
Clinical Immunology (Orlando, Fla.)|April 27, 2012
IgE recognition of bullous pemphigoid (BP)180 and BP230 in BP patients and elderly individuals with pruritic dermatosesLuca Fania, Giacomo Caldarola, Ralf Müller, et al.
Frontiers in Medicine|November 7, 2022
Case report: Detection of anti-bullous pemphigoid antigen 180 antibodies in a patient with Behçet's diseaseDario Didona, Antonio Manuel Sequeira Santos, Tomas Cunha, et al.
Experimental Dermatology|July 18, 2006
IgG reactivity against non-conformational NH-terminal epitopes of the desmoglein 3 ectodomain relates to clinical activity and phenotype of pemphigus vulgarisRalf Müller, Vera Svoboda, Elke Wenzel, et al.
Experimental Dermatology|December 15, 2015
Induction of T regulatory cells by the superagonistic anti-CD28 antibody D665 leads to decreased pathogenic IgG autoantibodies against desmoglein 3 in a HLA-transgenic mouse model of pemphigus vulgarisThomas Schmidt, Sebastian Willenborg, Thomas Hünig, et al.
Dermatology (Basel, Switzerland)|February 18, 2006
Prolonged clinical remission of patients with severe pemphigus upon rapid removal of desmoglein-reactive autoantibodies by immunoadsorptionRüdiger Eming, Jürgen Rech, Sandra Barth, et al.
Pageof 18

Showing results (71-80 of 180) with videos related to

Sort By:
Pageof 18
Frontiers in Medicine|October 21, 2022
Therapeutic strategies for oral lichen planus: State of the art and new insightsDario Didona, Raffaele Dante Caposiena Caro, Antonio Manuel Sequeira Santos, et al.
Clinical Immunology (Orlando, Fla.)|November 23, 2006
Detection of low avidity desmoglein 3-reactive T cells in pemphigus vulgaris using HLA-DR beta 1*0402 tetramersChristian Veldman, Rüdiger Eming, Sonja Wolff-Franke, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|April 18, 2009
Results of a survey of German dermatologists on the therapeutic approaches to pemphigus and bullous pemphigoidSilke C Hofmann, Ocko Kautz, Michael Hertl, et al.
European Journal of Dermatology : EJD|October 17, 2018
Adjuvant high-dose intravenous immunoglobulins for recalcitrant erosive oral lichen planus: mixed clinical responsesArmin Bender, Caroline Fix, Verena Eubel, et al.
Journal of Dermatological Science|May 23, 2020
Detection of autoantibodies against alpha-2-macroglobulin-like 1 in paraneoplastic pemphigus sera utilizing novel green fluorescent protein-based immunoassaysCecilia Bazzini, Nadja Begré, Bertand Favre, et al.
Clinical Immunology (Orlando, Fla.)|April 27, 2012
IgE recognition of bullous pemphigoid (BP)180 and BP230 in BP patients and elderly individuals with pruritic dermatosesLuca Fania, Giacomo Caldarola, Ralf Müller, et al.
Frontiers in Medicine|November 7, 2022
Case report: Detection of anti-bullous pemphigoid antigen 180 antibodies in a patient with Behçet's diseaseDario Didona, Antonio Manuel Sequeira Santos, Tomas Cunha, et al.
Experimental Dermatology|July 18, 2006
IgG reactivity against non-conformational NH-terminal epitopes of the desmoglein 3 ectodomain relates to clinical activity and phenotype of pemphigus vulgarisRalf Müller, Vera Svoboda, Elke Wenzel, et al.
Experimental Dermatology|December 15, 2015
Induction of T regulatory cells by the superagonistic anti-CD28 antibody D665 leads to decreased pathogenic IgG autoantibodies against desmoglein 3 in a HLA-transgenic mouse model of pemphigus vulgarisThomas Schmidt, Sebastian Willenborg, Thomas Hünig, et al.
Dermatology (Basel, Switzerland)|February 18, 2006
Prolonged clinical remission of patients with severe pemphigus upon rapid removal of desmoglein-reactive autoantibodies by immunoadsorptionRüdiger Eming, Jürgen Rech, Sandra Barth, et al.
Pageof 18